13,620 results match your criteria Gynecologic oncology[Journal]


Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium.

Gynecol Oncol 2019 Feb 15. Epub 2019 Feb 15.

AIDS Malignancy Consortium, New York, NY, United States of America. Electronic address:

Purpose: To determine the feasibility, safety, and tolerability of concomitant chemoradiotherapy administered at standard doses in HIV-infected women with locally-advanced cervical cancer (LACC) receiving antiretroviral therapy (ART).

Patients And Methods: Eligible participants had HIV infection and untreated, histologically-confirmed, invasive carcinoma of the uterine cervix, FIGO stages IB2, IIA (if tumor >4 cm), IIB, IIIA, IIIB, or IVA and met standard eligibility criteria. Subjects were prescribed 41. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.023DOI Listing
February 2019

Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.

Gynecol Oncol 2019 Feb 13. Epub 2019 Feb 13.

CoRPS - Center of Research on Psychology in Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, the Netherlands; Netherlands Comprehensive Cancer Organisation, the Netherlands.

Objective: To assess long-term differences in health-related quality of life (HRQoL) of older ovarian cancer survivors compared to both an age-matched normative population and to younger survivors. In addition, the differential effect of chemotherapy on HRQoL between older and younger survivors was compared.

Methods: Ovarian cancer survivors (n = 348) diagnosed between 2000 and 2010, as registered by the Dutch population-based Eindhoven Cancer Registry, were invited to complete the EORTC QLQ-C30 HRQoL questionnaire in 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.001DOI Listing
February 2019
1 Read

Phase III trials in ovarian cancer: The evolving landscape of front line therapy.

Gynecol Oncol 2019 Feb 12. Epub 2019 Feb 12.

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Introduction: Ovarian cancer has a high mortality to case ratio. To improve the initial response to therapy, trials of biologic agents in combination with primary chemotherapy and as maintenance after completing chemotherapy are being conducted. Multiple trials are ongoing and this strategy has great promise. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.008DOI Listing
February 2019
1 Read

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.

Gynecol Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Medical Oncology, Rhode Island Hospital, United States of America. Electronic address:

Background: Intraperitoneal (IP) chemotherapy can improve outcomes for women with optimally cytoreduced epithelial ovarian cancer but toxicities are a concern. We conducted 2 phase 2 trials of an IV/IP regimen using carboplatin and paclitaxel without (Trial A) and with bevacizumab (Trial B).

Methods: Both trials consisted of carboplatin AUC 6 day 1, and paclitaxel 60 mg/m on days 1,8, 15 of a 21-day cycle; in Trial B, patients received IV bevacizumab 15 mg/kg every cycle starting cycle 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.004DOI Listing
February 2019

Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.

Gynecol Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Gynaecology and Gynaecologic Oncology, University Medical Center Hamburg-Eppendorf, Germany; Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

Objective: Lymph node ratio (LNR) can predict treatment outcome and prognosis in patients with solid tumors. Aim of the present analysis was to confirm the concept of using LNR for assessing outcome in patients with vulvar cancer after surgery with inguinal lymphadenectomy in a large multicenter project.

Methods: The AGO-CaRE-1 study multicenter database was used for analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.007DOI Listing
February 2019
1 Read

Implicit bias toward cervical cancer: Provider and training differences.

Gynecol Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Psychology, University of Arizona, USA. Electronic address:

Objective: Implicit prejudice and stereotyping may exist in health care providers automatically without their awareness. These biases can correlate with outcomes that are consequential for the patient. This study examined gynecologic oncology care providers' implicit prejudice and stereotyping toward cervical cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.013DOI Listing
February 2019
1 Read

Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.

Gynecol Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. Electronic address:

Objective: Germline mutations occurring in the highly penetrant genes BRCA1 and BRCA2 are responsible for only certain cases of familial breast cancer (BC) and ovarian cancer (OC). Thus, the use of NGS multi-gene panel (MGP) testing has recently become very popular.

Methods: To estimate a reliable BC and OC risk associated with pathogenic variants in the selected candidate BC/OC predisposition genes, a comprehensive meta-analysis of 48 MGP-based studies analyzing BC/OC patients was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.027DOI Listing
February 2019

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.

Gynecol Oncol 2019 Feb 1. Epub 2019 Feb 1.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, United States of America; Duke Cancer Institute, United States of America. Electronic address:

Objectives: A recent randomized controlled trial demonstrated an overall survival benefit to the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to neoadjuvant chemotherapy (NACT) for stage III epithelial ovarian cancer (EOC). The objective of the current study was to quantify the cost-effectiveness of HIPEC in this setting.

Methods: A decision analytic cost-effectiveness model was designed from a payer perspective to compare 2 surgical management strategies for EOC: (1) interval cytoreductive surgery (ICS); (2) ICS + HIPEC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.025DOI Listing
February 2019

A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.

Gynecol Oncol 2019 Feb 1. Epub 2019 Feb 1.

Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, United States of America. Electronic address:

Objective: Despite current guidelines recommending women with ovarian cancer receive genetic risk evaluation by a genetic counselor, utilization has historically been low. We sought to assess the feasibility and effectiveness of a week-long mobile Application for Genetic Information on Cancer (mAGIC) intervention aimed to persuade women with ovarian cancer to pursue genetic counseling.

Methods: The mobile application intervention was based on the Fogg Behavior Model, and consisted of three parts: (1) identifying barriers, (2) developing motivators, and (3) providing triggers to action. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.019DOI Listing
February 2019
1 Read

Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.

Gynecol Oncol 2019 Feb 1. Epub 2019 Feb 1.

Division of Clinical Epidemiology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland.

Objective: About 30% of women who are eligible for cervical cancer (CC) screening remain un-screened or under-screened in Switzerland. HPV testing on self-collected vaginal samples (Self-HPV) has shown to be more sensitive than cytology while also reaching non-attendees. The objective of this study was to explore the cost-effectiveness of offering Self-HPV to non-attendees in Switzerland. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193006
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.021DOI Listing
February 2019
6 Reads
3.774 Impact Factor

Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer.

Gynecol Oncol 2019 Feb 2. Epub 2019 Feb 2.

The Ohio State University, James Cancer Hospital, Division of Gynecologic Oncology, 320 West 10(th) Avenue, Columbus, OH 43210, USA. Electronic address:

Objective: The impact of pathologic features of a cone biopsy on the management of women with early stage cervical cancer is understudied. Our objective was to evaluate the additive value of pathologic features of a cone biopsy toward identifying patients with high risk tumors for which adjuvant therapy may be indicated.

Methods: Patients with early stage cervical cancer undergoing a conization followed by radical hysterectomy from 1995 to 2016 were retrospectively identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.026DOI Listing
February 2019
1 Read

Disparities in gynecologic cancer genetics evaluation.

Gynecol Oncol 2019 Jan 30. Epub 2019 Jan 30.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; Department of Health Services Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. Electronic address:

An estimated 2-5% of endometrial cancers and 15-20% of high-grade, non-mucinous epithelial ovarian cancers have an underlying hereditary cause. Appropriate risk assessment, genetic counseling, and germline genetic testing for cancer predisposition genes in both gynecologic cancer patients and their at-risk relatives is essential for effective delivery of tailored cancer treatment and cancer prevention. However, significant disparities exist within medically underserved and minority populations in the United States regarding awareness of, access to, and use of genetic services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.024DOI Listing
January 2019

Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.

Gynecol Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.

Objective: Gastric-type mucinous carcinoma (GAS) is a novel variant of mucinous carcinoma of the uterine cervix. As shown in the original Japanese group description, in recent studies, GAS represents a more aggressive disease than the usual-type endocervical adenocarcinoma (UEA). Detailed clinicopathological features of this variant remain to be elucidated in a larger series of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.022DOI Listing
January 2019
2 Reads

Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.

Gynecol Oncol 2019 Jan 28. Epub 2019 Jan 28.

AstraZeneca, Health Economics, Cambridge, United Kingdom.

Objective: Survival but not cure rates have improved for epithelial ovarian cancer (EOC), demonstrating the need for effective prevention. Targeted prevention in BRCA carriers by risk reducing surgery (RRS) prevents 80% of cases but incurs additional up-front costs, compensated for by the potential for long term savings from treatment avoidance. Does prevention represent value for money? In the absence of long-term data from prospective trials, determining the cost effectiveness of a prevention strategy requires economic modelling. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193006
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.018DOI Listing
January 2019
2 Reads

Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?

Gynecol Oncol 2019 02;152(2):221-222

Department of Obstetrics and Gynecology and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.005DOI Listing
February 2019
3.774 Impact Factor

Breastfeeding factors and risk of epithelial ovarian cancer.

Gynecol Oncol 2019 Jan 25. Epub 2019 Jan 25.

Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA. Electronic address:

Objective: Previous studies suggest that breastfeeding reduces epithelial ovarian cancer (EOC) risk. However, the effects of age, timing and episode details on the EOC-breastfeeding relationship have not been examined. The objective of this study was to examine the association between breastfeeding factors and epithelial ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.017DOI Listing
January 2019

A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.

Gynecol Oncol 2019 Jan 25. Epub 2019 Jan 25.

Department of Pathology, CHA Bundang Medical Center, CHA University, Republic of Korea; Institute for Clinical Research, CHA Bundang Medical Center, CHA University, Republic of Korea. Electronic address:

Objective: Ovarian cancer is the leading cause of gynecologic-related mortality worldwide. Despite successful initial treatment, overall survival rates are very low because tumors develop resistance to chemotherapeutic drugs. The PI3K/mTOR pathway is a key signaling pathway involved in drug resistance of ovarian cancer cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193004
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.012DOI Listing
January 2019
3 Reads

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Gynecol Oncol 2019 Jan 24. Epub 2019 Jan 24.

Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States of America; Department of Oncology, Mayo Clinic, Rochester, MN, United States of America. Electronic address:

Objective: Poly(ADP-ribose) polymerase (PARP) inhibitors have shown substantial activity in homologous recombination- (HR-) deficient ovarian cancer and are undergoing testing in other HR-deficient tumors. For reasons that are incompletely understood, not all patients with HR-deficient cancers respond to these agents. Preclinical studies have demonstrated that changes in alternative DNA repair pathways affect PARP inhibitor (PARPi) sensitivity in ovarian cancer models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.015DOI Listing
January 2019
1 Read

Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.

Gynecol Oncol 2019 Jan 21. Epub 2019 Jan 21.

Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China. Electronic address:

Objective: This study aimed to evaluate the efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young patients with endometrial atypical hyperplasia (EAH) and early stage endometrial cancer (EEC) who wished to preserve their fertility.

Methods: Patients with EAH (n = 120) or well-differentiated EEC (n = 40, FIGO stage IA, without myometrial invasion) were retrospectively included. All patients received constant oral progestin combined with hysteroscopic evaluation every 3 months until achieving complete response (CR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.014DOI Listing
January 2019
1 Read

Brachytherapy: A critical component of primary radiation therapy for cervical cancer: For the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).

Gynecol Oncol 2019 Jan 17. Epub 2019 Jan 17.

Radiation Oncology, UC San Diego School of Medicine, San Diego, CA, United States of America.

Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cervical cancer. A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques. Conformal external beam therapies such intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cervical cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.10.016DOI Listing
January 2019

The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.

Gynecol Oncol 2019 Jan 17. Epub 2019 Jan 17.

Division of Gynecologic Oncology, Duke Cancer Institute, Durham, NC, United States of America.

Background: Granulosa cell tumors (GCT) variably express estrogen receptors (ER) and progesterone receptors (PR). The goal of this study is to evaluate the relationship between ER and PR expression patterns and clinical outcomes in women with GCT.

Methods: A multicenter, retrospective analysis was performed of all cases of GCT diagnosed between 1989 and 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.016DOI Listing
January 2019
1 Read

Modified rectus abdominis myoperitoneal flap for pelvic floor reconstruction.

Gynecol Oncol 2019 Jan 17. Epub 2019 Jan 17.

Institute of Anatomy, First Faculty of Medicine, Charles University in Prague, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.004DOI Listing
January 2019

Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

Gynecol Oncol 2019 Jan 17. Epub 2019 Jan 17.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States of America. Electronic address:

Women with germline BRCA1 or BRCA2 (BRCA) mutations, are recommended risk-reducing salpingo-oophorectomy (RRSO) prior to menopause. Surgical menopause has significant impact on patients' health and well-being. Subsequently, concerns about surgical menopause influence uptake of RRSO in high risk women. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183151
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.014DOI Listing
January 2019
5 Reads

Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer.

Gynecol Oncol 2019 Jan 16. Epub 2019 Jan 16.

Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.

Objective: The optimal adjuvant management of women with FIGO Stage III-IVA endometrial cancer (EC) is unclear. While recent prospective data suggest that treatment with pelvic radiotherapy (RT) prior to chemotherapy (CT) is not associated with a survival benefit compared to CT alone, no prospective randomized trial has included a treatment arm in which CT is given before RT.

Methods: An observational cohort study was performed on women with FIGO Stage III-IVA Type 1 (grade 1-2, endometrioid) EC who underwent hysterectomy and received multi-agent CT and/or RT from 2004 to 2014 at Commission on Cancer-accredited hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.007DOI Listing
January 2019
1 Read

The application of fibrin sealant for the prevention of lymphocele after lymphadenectomy in patients with gynecological malignancies: A systematic review and meta-analysis of randomized controlled trials.

Gynecol Oncol 2019 Jan 16. Epub 2019 Jan 16.

Department of Gynecological Oncology, Metaxa Memorial Cancer Hospital, Piraeus, Greece.

Purpose: The aim of the present study was to evaluate the correlation between the use of fibrin-collagen sealants on lymph node dissection areas and formation of lymphocele after lymphadenectomy in patients with gynecological malignancies.

Materials And Methods: A systematic search of 5 electronic databases for articles published up to November 2018 was performed. All randomized controlled clinical trials (RCTs) which reported outcomes after application of fibrin collagen agents in patients who underwent lymphadenectomy for gynecological malignancies, were finally included in the present meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.011DOI Listing
January 2019
2 Reads

Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

Gynecol Oncol 2019 Jan 15. Epub 2019 Jan 15.

Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, United States. Electronic address:

Objective: Natural killer (NK) cells are lymphocytes well suited for adoptive immunotherapy. Attempts with adoptive NK cell immunotherapy against ovarian cancer have proven unsuccessful, with the main limitations including failure to expand and diminished effector function. We investigated if incubation of NK cells with interleukin (IL)-12, IL-15, and IL-18 for 16 h could produce cytokine-induced memory-like (CIML) NK cells capable of enhanced function against ovarian cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193003
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.006DOI Listing
January 2019
5 Reads

Apatinib exerts anti-tumour effects on ovarian cancer cells.

Gynecol Oncol 2019 Jan 14. Epub 2019 Jan 14.

Department of Gynecology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150040, Heilongjiang Province, China. Electronic address:

Objective: Apatinib, a small molecule inhibitor of VEGFR-2 tyrosine kinase, shows strong anti-tumour activity against various tumours. The function of apatinib in ovarian cancer, however, remains unclear. This study was conducted to investigate the effects and potential mechanisms by which apatinib modulates the biological function of ovarian cancer cells in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193004
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.010DOI Listing
January 2019
4 Reads

Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.

Gynecol Oncol 2019 Jan 14. Epub 2019 Jan 14.

Washington University School of Medicine St. Louis, St Louis, MO, USA.

Objectives: Premenopausal women may undergo surgical menopause after staging for their endometrial cancer. Our aim was to determine the association between body mass index (BMI) and surgical menopausal symptoms.

Methods: We report a retrospective review of endometrial cancer patients whom underwent menopause secondary to their surgical staging procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.009DOI Listing
January 2019

CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.

Gynecol Oncol 2019 Jan 11. Epub 2019 Jan 11.

Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America.

Objective: A scoring system has been proposed to predict gross residual disease at primary debulking surgery (PDS) for advanced epithelial ovarian cancer. This scoring system has not been assessed in patients undergoing neoadjuvant chemotherapy (NACT). The aim of this study is to assess the reproducibility and prognostic significance of the scoring system when applied to women undergoing NACT followed by interval debulking surgery (IDS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.012DOI Listing
January 2019

Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.

Gynecol Oncol 2019 Jan 12. Epub 2019 Jan 12.

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.

Objective: To compare survival outcomes of minimally invasive surgery (MIS) and conventional open surgery for radical hysterectomy (RH) among patients with early-stage cervical cancer (CC).

Methods: We retrospectively identified stage IB1-IIA2 CC patients who underwent either laparoscopic or open Type C RH between 2000 and 2018. Patients' clinicopathologic characteristics and survival outcomes were compared according to the surgical approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.008DOI Listing
January 2019
2 Reads

Pelvic lymphadenectomy by vaginal natural orifice transluminal endoscopic surgery (vNOTES) for early-stage endometrial cancer.

Gynecol Oncol 2019 Jan 11. Epub 2019 Jan 11.

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193000
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.003DOI Listing
January 2019
3 Reads

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

Gynecol Oncol 2019 Jan 9. Epub 2019 Jan 9.

Dana-Farber Cancer Institute, Boston, MA, USA.

Objective: To analyze the safety and efficacy of niraparib in patients aged ≥70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial.

Methods: The trial enrolled 2 independent cohorts with histologically diagnosed recurrent ovarian, fallopian tube, or peritoneal cancer who responded to platinum rechallenge, on the basis of germline breast cancer susceptibility gene mutation (gBRCAmut) status. Patients were randomized 2:1 to receive niraparib (300 mg) or placebo once daily until disease progression. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183147
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.009DOI Listing
January 2019
8 Reads

Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.

Gynecol Oncol 2019 Jan 9. Epub 2019 Jan 9.

Becton, Dickinson and Company, BD Life Sciences, - Diagnostic Systems, 7 Loveton Circle, Sparks, MD 21152, USA. Electronic address:

Objectives: Increasing evidence suggests that extended human papillomavirus (HPV) genotyping (beyond 16/18) is effective for risk stratification in women with normal cytology. This report provides extended genotyping results, using the BD Onclarity HPV Assay, for individual genotypes HPV16, 18, 31, 45, 51, and 52 ̶ and three pooled genotype results for HPV33/58, 35/39/68, and 56/59/66.

Methods: 27,037 women with normal cytology, ≥25 years, were enrolled into the Onclarity HPV trial during routine screening. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183153
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.024DOI Listing
January 2019
6 Reads

Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.

Gynecol Oncol 2019 Jan 10. Epub 2019 Jan 10.

Gynecologic Oncology, Princess Margaret Cancer Centre, The University Health Network, Toronto, ON, Canada. Electronic address:

Objective: Genetic testing identifies cancer patients who may benefit from targeted treatment and allows for enhanced cancer screening and risk-reduction in their at-risk relatives. Traditional models of genetic counseling (GC) cannot meet the increasing demand and urgency for genetic testing. The objective of this study was to evaluate a new model of service delivery to improve the efficiency of pre-test GC for panel-based genetic testing. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183154
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.027DOI Listing
January 2019
4 Reads

Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease.

Gynecol Oncol 2019 Jan 8. Epub 2019 Jan 8.

Department of Obstetrics and Gynecology, University of Tuebingen, Germany.

Objective: Hysterectomy is a frequently used therapeutic option for benign gynecological conditions. The purpose of this study was to investigate the incidence and characteristics of unforeseen malignant pathologies of the uterine corpus in a large population-based, single center cohort.

Methods: Patients who underwent hysterectomy for presumed benign conditions between 2003 and 2016 were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.026DOI Listing
January 2019
2 Reads

Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?

Gynecol Oncol 2019 Jan 8. Epub 2019 Jan 8.

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States of America; Dana-Farber Cancer Institute, Boston, MA, United States of America.

Objectives: To determine whether perioperative red blood cell transfusion (PRBCT) affects infection, thrombosis, or survival rates in epithelial ovarian cancer (EOC) patients undergoing neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS).

Methods: Demographics, operative characteristics, and outcome data were abstracted from records of stage IIIC-IV EOC patients managed with NACT-IDS from 01/2010-07/2015. Associations of PRBCT with morbidity and oncologic outcomes were evaluated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193000
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.001DOI Listing
January 2019
8 Reads

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Gynecol Oncol 2019 Jan 7. Epub 2019 Jan 7.

Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address:

Objective: Aberrant expression of HER2/neu and PIK3CA gene products secondary to amplification/mutations are common in high-grade-serous-endometrial (USC) and ovarian-cancers (HGSOC). Because scant information is currently available in the literature on the potential negative effect of PIK3CA mutations on the activity of afatinib, in this study we evaluate for the first time the role of oncogenic PIK3CA mutations as a potential mechanism of resistance to afatinib in HGSOC and USC overexpressing HER2/neu.

Methods: We used six whole-exome-sequenced primary HGSOC/USC cell-lines and three xenografts overexpressing HER2/neu and harboring mutated or wild-type PIK3CA/PIK3R1 genes to evaluate the role of PI3K-mutations as potential mechanism of resistance to afatinib, an FDA-approved pan-c-erb-inhibitor in clinical trials in USC. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193000
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.01.002DOI Listing
January 2019
6 Reads
3.774 Impact Factor

Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.

Gynecol Oncol 2019 Jan 7. Epub 2019 Jan 7.

Department of Gynecology, Huzhou Maternity&Child Health Care Hospital, Huzhou, Zhejiang Province, China. Electronic address:

Objectives: This study aimed to assess human papilloma virus (HPV) 16 18/45 typing test results combined with cytology for cervical exfoliated cells from women who screened positive in an HPV E6/E7 mRNA assay (Aptima HPV, AHPV).

Methods: In total, 3257 AHPV-positive women aged 25-65 years were underwent AHPV 16 18/45 Genotype assay (AHPV-GT) testing with cytology. Women were referred for colposcopy and further biopsy if indicated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183154
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.028DOI Listing
January 2019
14 Reads

MUC16 suppresses human and murine innate immune responses.

Gynecol Oncol 2019 Jan 6. Epub 2019 Jan 6.

Department of Obstetrics and Gynecology, University of Wisconsin, Madison, WI, USA. Electronic address:

Objective: MUC16, the mucin that contains the CA125 epitopes, suppresses the cytolytic responses of human NK cells and inhibits the efficacy of therapeutic antibodies. Here, we provide further evidence of the regulatory role of MUC16 on human and murine NK cells and macrophages.

Methods: Target cell cytolysis and doublet formation assays were performed to assess effects of MUC16 on human NK cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183153
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.023DOI Listing
January 2019
7 Reads

Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.

Gynecol Oncol 2019 Jan 4. Epub 2019 Jan 4.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.

Objective: The anti-thrombogenic effects of statins and aspirin have been reported in various malignancies but have not been well examined in endometrial cancer. This study examined the association between statin and/or aspirin use and venous thromboembolism (VTE) risk in endometrial cancer.

Methods: This is a multi-center retrospective study examining 2527 women with endometrial cancer between 2000 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.020DOI Listing
January 2019
1 Read

Endocrine therapy in endometrial cancer: An old dog with new tricks.

Gynecol Oncol 2019 Jan 4. Epub 2019 Jan 4.

Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address:

One of the most prevalent potential therapeutic targets for women with endometrioid endometrial cancer (EC) is the estrogen receptor (ER)/progesterone receptor (PR) pathway. Despite a high proportion of endometrioid ECs being ER and/or PR positive, endocrine therapy is only effective in a minority of women with EC and ultimately patients progress with resistance developing to treatment. A variety of treatment approaches with progestins, selective ER modulators (SERMs) and aromatase inhibitors (AIs) are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.018DOI Listing
January 2019

Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.

Gynecol Oncol 2019 Jan 3. Epub 2019 Jan 3.

Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States of America. Electronic address:

Objectives: We sought to examine the relationship between frailty and complicated postoperative courses, including intensive care unit (ICU) admission and non-home discharge, in patients with advanced ovarian cancer (OC) undergoing primary debulking surgery (PDS) for curative intent.

Methods: Patients were identified from a retrospectively collected database at a single institution between 1/1/2003-12/31/2011. A frailty index was derived from 30 items representing comorbidities and activities of daily living, each scored as 0, 0. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183153
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.025DOI Listing
January 2019
6 Reads

Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.

Gynecol Oncol 2019 Jan 3. Epub 2019 Jan 3.

St Thomas Health, Nashville, TN, United States of America.

Objective: We explored the germline mutation spectrum and prevalence among 1650 women with breast and uterine cancer (BUC) who underwent multi-gene hereditary cancer panel testing at a single commercial laboratory.

Methods: The combined frequency of mutations in 23 BC and/or UC genes was compared between BUC cases and control groups with (1) no personal cancer history; (2) BC only; and (3) UC only using logistic regression.

Results: Fourteen percent (n = 231) of BUC cases tested positive for mutations in BC and/or UC genes and were significantly more likely to test positive than individuals with BC only (P < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.021DOI Listing
January 2019
1 Read

Cancer susceptibility gene mutations in type I and II endometrial cancer.

Gynecol Oncol 2019 01 26;152(1):20-25. Epub 2018 Oct 26.

Mayo Clinic, Division of Gynecologic Oncology, United States of America.

Objectives: To determine the incidence of germline cancer predisposition gene mutations in patients with endometrial cancer (EC) subtypes.

Methods: Germline DNA was extracted from whole blood collected from consenting patients undergoing primary surgery for EC between 5/2005 and 11/2016. DNA samples were evaluated by product sequencing from a targeted multiplex PCR panel including 21 known/suspected cancer predisposition genes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183130
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.10.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326093PMC
January 2019
5 Reads

Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution.

Gynecol Oncol 2019 01;152(1):1-2

Division of Gynecologic Oncology, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.004DOI Listing
January 2019
1 Read

Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer.

Gynecol Oncol 2018 Dec 29. Epub 2018 Dec 29.

Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America. Electronic address:

Background: Limited outcome data exists on salvage re-irradiation for vaginal relapse of previously-irradiated endometrial cancer. We report our 10-year experience with management of vaginal recurrence using definitive intent re-irradiation brachytherapy with or without EBRT.

Methods: A retrospective review was performed on 22 patients treated with definitive-intent re-irradiation brachytherapy ± EBRT for vaginal recurrence of endometrial cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.022DOI Listing
December 2018
1 Read

Hospice utilization in advanced cervical malignancies: An analysis of the National Inpatient Sample.

Gynecol Oncol 2018 Dec 23. Epub 2018 Dec 23.

Division of Gynecologic Oncology, SUNY Downstate Medical Center, United States of America.

Objective: Hospice services improve quality of life and outcomes for patients and caretakers, compared to inpatient mortality. This study identifies factors that exert the strongest influence on end-of-life care modalities in patients with cervical cancer.

Methods: Admissions with a diagnosis of cervical cancer that were discharged to hospice or died in-hospital were identified in the National Inpatient Sample years 2007-2011, excluding admissions coded for hysterectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.016DOI Listing
December 2018

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Gynecol Oncol 2018 Dec 23. Epub 2018 Dec 23.

Memorial Sloan Kettering Cancer Center, Medical Oncology, New York, NY 10065, United States of America. Electronic address:

Introduction: Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer.

Methods: This was an open label, 1:1 randomized study of cabozantinib 60 mg orally (PO) daily versus weekly paclitaxel 80 mg/m given 3 out of 4 weeks (NCT01716715); 111 patients were enrolled. Eligibility included persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and at least one but no >3 prior chemotherapy regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.008DOI Listing
December 2018
2 Reads

Genomic characterization of cervical cancer based on human papillomavirus status.

Gynecol Oncol 2018 Dec 20. Epub 2018 Dec 20.

Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, PR China. Electronic address:

Objective: It is uncommon for cervical cancer patients to be diagnosed without a human papillomavirus (HPV) infection. As prophylactic vaccines against high-risk HPV types are an ineffective preventive measure for these patients it is essential to identify differential biomarkers that may be associated with detection, prognosis and novel targeted therapies. The objective of this study was to compare the two entities, HPV+ and HPV- cervical cancers, based on TCGA public data. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183151
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.017DOI Listing
December 2018
7 Reads

Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.

Gynecol Oncol 2019 02 20;152(2):322-327. Epub 2018 Dec 20.

Department of Obstetrics and Gynecology, The University of Chicago, Chicago, IL, USA; Department of Medicine-Geriatrics, The University of Chicago, Chicago, IL, USA; The Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA; The MacLean Center on Clinical Medical Ethics, The University of Chicago, Chicago, IL, USA.

Objective: To examine endometrial cancer survivors' access to recommended obesity-related self-care resources.

Methods: Participants included women treated 2010-2015 for endometrial cancer at an academic medical center who lived in the surrounding 16 ZIP code area on Chicago's South Side. Demographic and health data were abstracted from medical records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.005DOI Listing
February 2019